Last reviewed · How we verify

NCT05828576

ECAA Brain MRI: Seeking the Link Between Extracranial Carotid Artery Aneurysms and Small Vessel Disease

Status unknown Last updated 25 April 2023
What this trial tests

trial testing MRI in Extracranial Carotid Artery Aneurysm in 50 participants. Status unknown.

Timeline
30 March 2023
Primary endpoint
1 April 2025
1 April 2025

Quick facts

Lead sponsorUMC Utrecht
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date30 March 2023
Primary completion1 April 2025
Estimated completion1 April 2025
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

UMC Utrecht — full company profile →

Who can join

18 and older, any sex, with Extracranial Carotid Artery Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In order to understand which ECAA patients benefit from medical therapy, more should be known about the possible outcomes of this rare disease. Small vessel disease seen on brain MRI's could be a good marker to assess possible silent cerebrovascular disease caused by ECAA's, suggesting underlying generalized vascular disease. With this knowledge, medical therapy for ECAA patients can be optimized and individualized to treat possible generalized vascular disease, aiding physicians in choosing a treatment strategy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other UMC Utrecht trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05828576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing